David Klein




My research follows two major themes: (1) health policy and (2) sepsis and critical illness.   In the area of health policy, I co-lead the Centre for the Evaluation and Optimization of Public Healthcare Finance at IHPME with Dr. Adalsteinn Brown.  We are focused on improving healthcare capital investment and evaluation with a multidisciplinary group of collaborators.   In the area of sepsis and critical illness, I lead several efforts to develop novel diagnostics and therapeutics.  I have particular expertise in healthcare innovation and commercialization in addition to clinical development strategy.

Please note: Dr. Klein is not taking any summer students.

Recent Publications

  1. Maitland, SB, Brauer, P, Mutch, DM, Royall, D, Klein, D, Tremblay, A et al.. Evaluation of Latent Models Assessing Physical Fitness and the Healthy Eating Index in Community Studies: Time-, Sex-, and Diabetes-Status Invariance. Nutrients. 2021;13 (12):. doi: 10.3390/nu13124258. PubMed PMID:34959810 PubMed Central PMC8708138.
  2. Freudenberg, N, Lee, K, Buse, K, Collin, J, Crosbie, E, Friel, S et al.. Defining Priorities for Action and Research on the Commercial Determinants of Health: A Conceptual Review. Am J Public Health. 2021;111 (12):2202-2211. doi: 10.2105/AJPH.2021.306491. PubMed PMID:34878875 PubMed Central PMC8667845.
  3. Lee, K, Freudenberg, N, Zenone, M, Smith, J, Mialon, M, Marten, R et al.. Measuring the Commercial Determinants of Health and Disease: A Proposed Framework. Int J Health Serv. 2022;52 (1):115-128. doi: 10.1177/00207314211044992. PubMed PMID:34723675 PubMed Central PMC8592108.
  4. Klein, DE, Lima, JM. The Prison Industrial Complex as a Commercial Determinant of Health. Am J Public Health. 2021;111 (10):1750-1752. doi: 10.2105/AJPH.2021.306467. PubMed PMID:34529500 PubMed Central PMC8561192.
  5. REMAP-CAP Investigators, ACTIV-4a Investigators, ATTACC Investigators, Goligher, EC, Bradbury, CA, McVerry, BJ et al.. Therapeutic Anticoagulation with Heparin in Critically Ill Patients with Covid-19. N Engl J Med. 2021;385 (9):777-789. doi: 10.1056/NEJMoa2103417. PubMed PMID:34351722 PubMed Central PMC8362592.
  6. ATTACC Investigators, ACTIV-4a Investigators, REMAP-CAP Investigators, Lawler, PR, Goligher, EC, Berger, JS et al.. Therapeutic Anticoagulation with Heparin in Noncritically Ill Patients with Covid-19. N Engl J Med. 2021;385 (9):790-802. doi: 10.1056/NEJMoa2105911. PubMed PMID:34351721 PubMed Central PMC8362594.
  7. Arabi, YM, Gordon, AC, Derde, LPG, Nichol, AD, Murthy, S, Beidh, FA et al.. Lopinavir-ritonavir and hydroxychloroquine for critically ill patients with COVID-19: REMAP-CAP randomized controlled trial. Intensive Care Med. 2021;47 (8):867-886. doi: 10.1007/s00134-021-06448-5. PubMed PMID:34251506 PubMed Central PMC8274471.
  8. REMAP-CAP Investigators, Gordon, AC, Mouncey, PR, Al-Beidh, F, Rowan, KM, Nichol, AD et al.. Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19. N Engl J Med. 2021;384 (16):1491-1502. doi: 10.1056/NEJMoa2100433. PubMed PMID:33631065 PubMed Central PMC7953461.
  9. Bao, EL, Nandakumar, SK, Liao, X, Bick, AG, Karjalainen, J, Tabaka, M et al.. Inherited myeloproliferative neoplasm risk affects haematopoietic stem cells. Nature. 2020;586 (7831):769-775. doi: 10.1038/s41586-020-2786-7. PubMed PMID:33057200 PubMed Central PMC7606745.
  10. STARRT-AKI Investigators, Canadian Critical Care Trials Group, Australian and New Zealand Intensive Care Society Clinical Trials Group, United Kingdom Critical Care Research Group, Canadian Nephrology Trials Network, Irish Critical Care Trials Group et al.. Timing of Initiation of Renal-Replacement Therapy in Acute Kidney Injury. N Engl J Med. 2020;383 (3):240-251. doi: 10.1056/NEJMoa2000741. PubMed PMID:32668114 .
Search PubMed

Affiliations & Other Activities

  • Head of Business Strategy, Applied Health Research Centre, Li Ka Shing Knowledge Institute, St. Michael’s Hospital
  • Staff Physician, Critical Care, St. Michael’s Hospital
  • Assistant Professor, Faculty of Medicine, University of Toronto
  • Member, Institute for Health Policy, Management, and Evaluation, Dalla Lana School of Public Health